25 XP   0   0   10

Fate Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Fate Therapeutics Inc together

PenkeI guess you are interested in Fate Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Fate Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Fate Therapeutics Inc

I send you an email if I find something interesting about Fate Therapeutics Inc.

Quick analysis of Fate Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Fate Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$3.24
Expected worth in 1 year
$2.22
How sure are you?
22.5%

+ What do you gain per year?

Total Gains per Share
$-1.02
Return On Investment
-18.0%

For what price can you sell your share?

Current Price per Share
$5.64
Expected price per share
$4.13 - $8.83
How sure are you?
50%

1. Valuation of Fate Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$5.64

Intrinsic Value Per Share

$-19.69 - $-11.75

Total Value Per Share

$-16.46 - $-8.51

2. Growth of Fate Therapeutics Inc (5 min.)




Is Fate Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$368.4m$553.9m-$132.3m-31.4%

How much money is Fate Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$37.8m-$63.7m$25.9m68.7%
Net Profit Margin-2,656.5%-332.4%--

How much money comes from the company's main activities?

3. Financial Health of Fate Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#153 / 1019

Most Revenue
#257 / 1019

Most Profit
#847 / 1019

Most Efficient
#874 / 1019

What can you expect buying and holding a share of Fate Therapeutics Inc? (5 min.)

Welcome investor! Fate Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Fate Therapeutics Inc.

What can you expect buying and holding a share of Fate Therapeutics Inc?

First you should know what it really means to hold a share of Fate Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Fate Therapeutics Inc is $5.64. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Fate Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Fate Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.24. Based on the TTM, the Book Value Change Per Share is $-0.25 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.43 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Fate Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.39-6.9%-0.35-6.3%-0.62-11.0%-0.41-7.2%-0.25-4.4%
Usd Book Value Change Per Share-0.30-5.4%-0.25-4.5%-0.43-7.6%0.091.6%0.071.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.010.2%
Usd Total Gains Per Share-0.30-5.4%-0.25-4.5%-0.43-7.6%0.091.6%0.081.4%
Usd Price Per Share3.74-4.08-24.01-32.99-19.58-
Price to Earnings Ratio-2.41--3.73--9.69--21.08--19.40-
Price-to-Total Gains Ratio-12.38--33.30--56.22--91.29--69.89-
Price to Book Ratio1.16-1.09-4.78-8.62-11.12-
Price-to-Total Gains Ratio-12.38--33.30--56.22--91.29--69.89-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share5.64
Number of shares177
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.250.09
Usd Total Gains Per Share-0.250.09
Gains per Quarter (177 shares)-44.9316.37
Gains per Year (177 shares)-179.7165.48
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-180-19016555
20-359-3702129120
30-539-5502194185
40-719-7303259250
50-899-9104323315
60-1078-10905388380
70-1258-12705453445
80-1438-14506518510
90-1617-16307582575
100-1797-18108647640

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%0.046.01.00.0%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%8.032.00.020.0%10.035.02.021.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%1.00.019.05.0%4.00.036.010.0%4.00.043.08.5%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%9.031.00.022.5%11.034.02.023.4%

Fundamentals of Fate Therapeutics Inc

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-11 07:38:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Fate Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Fate Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Fate Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -2,632.6% means that $-26.33 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Fate Therapeutics Inc:

  • The MRQ is -2,632.6%. The company is making a huge loss. -2
  • The TTM is -2,656.5%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,632.6%TTM-2,656.5%+23.9%
TTM-2,656.5%YOY-332.4%-2,324.1%
TTM-2,656.5%5Y-1,006.2%-1,650.3%
5Y-1,006.2%10Y-925.1%-81.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,632.6%-196.9%-2,435.7%
TTM-2,656.5%-211.2%-2,445.3%
YOY-332.4%-279.3%-53.1%
5Y-1,006.2%-436.8%-569.4%
10Y-925.1%-599.3%-325.8%
1.1.2. Return on Assets

Shows how efficient Fate Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Fate Therapeutics Inc to the Biotechnology industry mean.
  • -8.7% Return on Assets means that Fate Therapeutics Inc generated $-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Fate Therapeutics Inc:

  • The MRQ is -8.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -6.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.7%TTM-6.9%-1.8%
TTM-6.9%YOY-8.2%+1.3%
TTM-6.9%5Y-7.6%+0.7%
5Y-7.6%10Y-10.4%+2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.7%-13.6%+4.9%
TTM-6.9%-12.9%+6.0%
YOY-8.2%-11.9%+3.7%
5Y-7.6%-14.2%+6.6%
10Y-10.4%-16.2%+5.8%
1.1.3. Return on Equity

Shows how efficient Fate Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Fate Therapeutics Inc to the Biotechnology industry mean.
  • -12.0% Return on Equity means Fate Therapeutics Inc generated $-0.12 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Fate Therapeutics Inc:

  • The MRQ is -12.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -9.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-12.0%TTM-9.3%-2.7%
TTM-9.3%YOY-11.6%+2.3%
TTM-9.3%5Y-10.8%+1.5%
5Y-10.8%10Y-15.9%+5.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-12.0%-17.0%+5.0%
TTM-9.3%-16.1%+6.8%
YOY-11.6%-15.4%+3.8%
5Y-10.8%-20.0%+9.2%
10Y-15.9%-21.1%+5.2%

1.2. Operating Efficiency of Fate Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Fate Therapeutics Inc is operating .

  • Measures how much profit Fate Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Fate Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -2,868.4% means the company generated $-28.68  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Fate Therapeutics Inc:

  • The MRQ is -2,868.4%. The company is operating very inefficient. -2
  • The TTM is -3,126.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-2,868.4%TTM-3,126.1%+257.6%
TTM-3,126.1%YOY-396.3%-2,729.8%
TTM-3,126.1%5Y-1,091.5%-2,034.6%
5Y-1,091.5%10Y-952.2%-139.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2,868.4%-282.4%-2,586.0%
TTM-3,126.1%-225.8%-2,900.3%
YOY-396.3%-288.4%-107.9%
5Y-1,091.5%-475.2%-616.3%
10Y-952.2%-624.7%-327.5%
1.2.2. Operating Ratio

Measures how efficient Fate Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 29.68 means that the operating costs are $29.68 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Fate Therapeutics Inc:

  • The MRQ is 29.684. The company is inefficient in keeping operating costs low. -1
  • The TTM is 33.475. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ29.684TTM33.475-3.791
TTM33.475YOY5.056+28.419
TTM33.4755Y14.090+19.385
5Y14.09010Y15.590-1.500
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ29.6842.994+26.690
TTM33.4753.247+30.228
YOY5.0563.766+1.290
5Y14.0905.675+8.415
10Y15.5907.857+7.733

1.3. Liquidity of Fate Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Fate Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.48 means the company has $8.48 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Fate Therapeutics Inc:

  • The MRQ is 8.481. The company is very able to pay all its short-term debts. +2
  • The TTM is 8.767. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.481TTM8.767-0.286
TTM8.767YOY5.947+2.820
TTM8.7675Y7.619+1.148
5Y7.61910Y7.448+0.171
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.4813.930+4.551
TTM8.7674.251+4.516
YOY5.9475.436+0.511
5Y7.6196.045+1.574
10Y7.4486.383+1.065
1.3.2. Quick Ratio

Measures if Fate Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Fate Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 15.12 means the company can pay off $15.12 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Fate Therapeutics Inc:

  • The MRQ is 15.123. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 15.857. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.123TTM15.857-0.735
TTM15.857YOY10.631+5.226
TTM15.8575Y12.288+3.569
5Y12.28810Y10.303+1.984
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.1233.629+11.494
TTM15.8574.065+11.792
YOY10.6315.390+5.241
5Y12.2885.993+6.295
10Y10.3036.277+4.026

1.4. Solvency of Fate Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Fate Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Fate Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27 means that Fate Therapeutics Inc assets are financed with 27.2% credit (debt) and the remaining percentage (100% - 27.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Fate Therapeutics Inc:

  • The MRQ is 0.272. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.256. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.272TTM0.256+0.016
TTM0.256YOY0.291-0.035
TTM0.2565Y0.281-0.025
5Y0.28110Y0.307-0.026
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2720.332-0.060
TTM0.2560.333-0.077
YOY0.2910.268+0.023
5Y0.2810.366-0.085
10Y0.3070.390-0.083
1.4.2. Debt to Equity Ratio

Measures if Fate Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Fate Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 37.4% means that company has $0.37 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Fate Therapeutics Inc:

  • The MRQ is 0.374. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.345. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.374TTM0.345+0.029
TTM0.345YOY0.413-0.068
TTM0.3455Y0.397-0.052
5Y0.39710Y0.477-0.081
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3740.380-0.006
TTM0.3450.389-0.044
YOY0.4130.334+0.079
5Y0.3970.432-0.035
10Y0.4770.465+0.012

2. Market Valuation of Fate Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Fate Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Fate Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -2.41 means the investor is paying $-2.41 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Fate Therapeutics Inc:

  • The EOD is -3.636. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.411. Based on the earnings, the company is expensive. -2
  • The TTM is -3.725. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.636MRQ-2.411-1.225
MRQ-2.411TTM-3.725+1.314
TTM-3.725YOY-9.693+5.968
TTM-3.7255Y-21.075+17.350
5Y-21.07510Y-19.404-1.671
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.636-2.426-1.210
MRQ-2.411-2.552+0.141
TTM-3.725-2.656-1.069
YOY-9.693-4.143-5.550
5Y-21.075-6.252-14.823
10Y-19.404-6.108-13.296
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Fate Therapeutics Inc:

  • The EOD is -4.357. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.890. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.478. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.357MRQ-2.890-1.468
MRQ-2.890TTM-3.478+0.588
TTM-3.478YOY-9.851+6.373
TTM-3.4785Y-23.765+20.288
5Y-23.76510Y-20.851-2.915
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.357-3.199-1.158
MRQ-2.890-3.259+0.369
TTM-3.478-3.552+0.074
YOY-9.851-5.617-4.234
5Y-23.765-8.326-15.439
10Y-20.851-8.689-12.162
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Fate Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.16 means the investor is paying $1.16 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Fate Therapeutics Inc:

  • The EOD is 1.742. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.155. Based on the equity, the company is underpriced. +1
  • The TTM is 1.087. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.742MRQ1.155+0.587
MRQ1.155TTM1.087+0.068
TTM1.087YOY4.779-3.692
TTM1.0875Y8.621-7.533
5Y8.62110Y11.125-2.504
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.7421.947-0.205
MRQ1.1552.116-0.961
TTM1.0872.095-1.008
YOY4.7792.836+1.943
5Y8.6213.443+5.178
10Y11.1253.791+7.334
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Fate Therapeutics Inc.

3.1. Institutions holding Fate Therapeutics Inc

Institutions are holding 91.884% of the shares of Fate Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Redmile Group, LLC13.22531.32381312442700
2023-12-31BlackRock Inc11.2990.001111212816-1271674-10.186
2023-12-31Vanguard Group Inc9.36480.00089293363-1614988-14.8051
2023-12-31Bellevue Group AG4.88890.2776485157900
2023-09-30D. E. Shaw & Co LP4.74790.010447116641122252.44
2023-12-31Johnson & Johnson3.4050.2881337906400
2023-09-30Jacobs Levy Equity Management, Inc.2.40750.032389123540052.3127
2023-12-31Acadian Asset Management LLC2.29870.033122811711315746.1209
2023-12-31Monaco Asset Management2.22.4031218322833528418.1436
2023-12-31JPMorgan Chase & Co2.08840.00072072506-522668-20.14
2023-12-31Casdin Capital, LLC2.06580.7526205000000
2023-09-30Citadel Advisors Llc2.03510.00092019632-262899-11.5179
2023-12-31Two Sigma Advisers, LLC1.89130.01641876900-55900-2.8922
2023-12-31Geode Capital Management, LLC1.87780.00071863485881414.9647
2023-12-31State Street Corporation1.87620.00031861919-410006-18.0466
2023-12-31Federated Hermes Inc1.86410.01721849872-601672-24.5426
2023-12-31Adage Capital Partners Gp LLC1.71310.0132170000017000000
2023-12-31Two Sigma Investments LLC1.56260.01331550659-100613-6.0931
2023-12-31Morgan Stanley - Brokerage Accounts1.33150.00041321356-108060-7.5597
2023-12-31Vestal Point Capital LP1.29990.5111129000012900000
Total 73.44295.694872882764-1237251-1.7%

3.2. Funds holding Fate Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-28SPDR® S&P Biotech ETF5.34270.59096079098766801.2775
2023-09-30BB Biotech AG Ord4.25350.4202483977900
2024-02-29Vanguard Total Stock Mkt Idx Inv2.25230.0012256268600
2024-03-28iShares Russell 2000 ETF1.83750.0234209078110080.0482
2023-12-31Vanguard Strategic Equity Inv1.48850.0813169366300
2023-12-31Vanguard Explorer Inv1.26430.0252143859400
2023-12-31Vanguard Strategic Small-Cap Equity Inv1.08250.30931231667568914.8427
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.08180.00861230957468263.9545
2023-12-31Federated Hermes MDT Small Cap Core IS1.03210.37221174363-230298-16.3953
2023-12-31Federated Hermes MDT SCC Institutional1.03210.37121174363-230299-16.3953
2024-02-29BlackRock Advantage Small Cap Core Instl0.79290.1823902234-450412-33.2986
2024-01-31Fidelity Small Cap Index0.7550.021385903872230.848
2024-03-28iShares Russell 2000 Value ETF0.70030.0466796802-505-0.0633
2024-03-31Direxion Daily S&P Biotech Bull 3X ETF0.64130.4289729657-5119-0.6967
2023-12-31Federated Hermes MDT Small Cap Growth IS0.52420.479596416-352853-37.171
2023-12-31Federated Hermes MDT SCG Institutional0.52420.4773596416-352853-37.171
2024-02-29JPMorgan Small Cap Value I0.4960.2915564337-39385-6.5237
2024-02-29Fidelity Extended Market Index0.47190.00995369017056415.1315
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.46280.0089526611105002.0344
2024-02-29JPM Thematics Genetic Thrps C2 Acc USD0.42330.4522481592-7287-1.4906
Total 26.45924.601430105955-1399319-4.6%

3.3. Insider Transactions

Insiders are holding 1.47% of the shares of Fate Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-01-29Edward J Dulac IiiSELL18495
2024-01-09Bahram ValamehrSELL112714.38
2024-01-09Cindy TahlSELL108744.37
2024-01-09Edward J Dulac IiiSELL70284.37
2024-01-09J Scott WolchkoSELL143914.37
2023-12-26Redmile Group, LlcBUY446303.72
2023-08-18Edward J Dulac IiiSELL47182.8
2023-08-04Yuan XuSELL6323.71
2023-07-05Brian T PowlSELL38544.87
2023-07-05Edward J Dulac IiiSELL51824.83
2023-06-14Yuan XuSELL34605.58
2023-04-20Redmile Group, LlcBUY200005.99
2023-04-18Yu-waye ChuSELL25326.57
2023-04-14Redmile Group, LlcBUY257006

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Fate Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.302-0.254-16%-0.428+42%0.091-430%0.070-533%
Book Value Per Share--3.2383.705-13%4.869-33%4.017-19%2.261+43%
Current Ratio--8.4818.767-3%5.947+43%7.619+11%7.448+14%
Debt To Asset Ratio--0.2720.256+6%0.291-7%0.281-3%0.307-11%
Debt To Equity Ratio--0.3740.345+8%0.413-9%0.397-6%0.477-22%
Dividend Per Share----0%-0%0.001-100%0.010-100%
Eps---0.388-0.354-9%-0.619+60%-0.407+5%-0.247-36%
Free Cash Flow Per Share---0.324-0.304-6%-0.623+93%-0.339+5%-0.203-37%
Free Cash Flow To Equity Per Share---0.325-0.304-7%-0.603+86%0.055-693%0.060-645%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---11.749--------
Intrinsic Value_10Y_min---19.695--------
Intrinsic Value_1Y_max---0.866--------
Intrinsic Value_1Y_min---1.893--------
Intrinsic Value_3Y_max---2.839--------
Intrinsic Value_3Y_min---5.792--------
Intrinsic Value_5Y_max---5.098--------
Intrinsic Value_5Y_min---9.774--------
Market Cap641736120.000+34%425548420.000464234640.000-8%2732214287.500-84%3753587387.000-89%2227956477.250-81%
Net Profit Margin---26.326-26.565+1%-3.324-87%-10.062-62%-9.251-65%
Operating Margin---28.684-31.261+9%-3.963-86%-10.915-62%-9.522-67%
Operating Ratio--29.68433.475-11%5.056+487%14.090+111%15.590+90%
Pb Ratio1.742+34%1.1551.087+6%4.779-76%8.621-87%11.125-90%
Pe Ratio-3.636-51%-2.411-3.725+54%-9.693+302%-21.075+774%-19.404+705%
Price Per Share5.640+34%3.7404.080-8%24.013-84%32.989-89%19.581-81%
Price To Free Cash Flow Ratio-4.357-51%-2.890-3.478+20%-9.851+241%-23.765+722%-20.851+622%
Price To Total Gains Ratio-18.677-51%-12.385-33.302+169%-56.219+354%-91.292+637%-69.889+464%
Quick Ratio--15.12315.857-5%10.631+42%12.288+23%10.303+47%
Return On Assets---0.087-0.069-21%-0.082-6%-0.076-13%-0.104+19%
Return On Equity---0.120-0.093-22%-0.116-3%-0.108-10%-0.159+33%
Total Gains Per Share---0.302-0.254-16%-0.428+42%0.092-427%0.080-478%
Usd Book Value--368417000.000421605250.000-13%553954500.000-33%457093750.000-19%257239350.000+43%
Usd Book Value Change Per Share---0.302-0.254-16%-0.428+42%0.091-430%0.070-533%
Usd Book Value Per Share--3.2383.705-13%4.869-33%4.017-19%2.261+43%
Usd Dividend Per Share----0%-0%0.001-100%0.010-100%
Usd Eps---0.388-0.354-9%-0.619+60%-0.407+5%-0.247-36%
Usd Free Cash Flow---36818000.000-34604000.000-6%-70943500.000+93%-38524750.000+5%-23088850.000-37%
Usd Free Cash Flow Per Share---0.324-0.304-6%-0.623+93%-0.339+5%-0.203-37%
Usd Free Cash Flow To Equity Per Share---0.325-0.304-7%-0.603+86%0.055-693%0.060-645%
Usd Market Cap641736120.000+34%425548420.000464234640.000-8%2732214287.500-84%3753587387.000-89%2227956477.250-81%
Usd Price Per Share5.640+34%3.7404.080-8%24.013-84%32.989-89%19.581-81%
Usd Profit---44122000.000-37804250.000-14%-63764000.000+45%-44498050.000+1%-27221200.000-38%
Usd Revenue--1676000.00015883250.000-89%24075000.000-93%12889650.000-87%6836800.000-75%
Usd Total Gains Per Share---0.302-0.254-16%-0.428+42%0.092-427%0.080-478%
 EOD+5 -3MRQTTM+5 -28YOY+19 -145Y+13 -2210Y+12 -23

4.2. Fundamental Score

Let's check the fundamental score of Fate Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.636
Price to Book Ratio (EOD)Between0-11.742
Net Profit Margin (MRQ)Greater than0-26.326
Operating Margin (MRQ)Greater than0-28.684
Quick Ratio (MRQ)Greater than115.123
Current Ratio (MRQ)Greater than18.481
Debt to Asset Ratio (MRQ)Less than10.272
Debt to Equity Ratio (MRQ)Less than10.374
Return on Equity (MRQ)Greater than0.15-0.120
Return on Assets (MRQ)Greater than0.05-0.087
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Fate Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.081
Ma 20Greater thanMa 506.790
Ma 50Greater thanMa 1006.945
Ma 100Greater thanMa 2005.284
OpenGreater thanClose5.800
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -1,8541,208-64659-58788-49951415
Income Tax Expense  -8,056-1,655-9,7115,330-4,381-359-4,74023,57218,832



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets506,217
Total Liabilities137,800
Total Stockholder Equity368,417
 As reported
Total Liabilities 137,800
Total Stockholder Equity+ 368,417
Total Assets = 506,217

Assets

Total Assets506,217
Total Current Assets331,540
Long-term Assets174,677
Total Current Assets
Cash And Cash Equivalents 41,870
Short-term Investments 273,305
Net Receivables 2,726
Other Current Assets 13,639
Total Current Assets  (as reported)331,540
Total Current Assets  (calculated)331,540
+/-0
Long-term Assets
Property Plant Equipment 158,511
Long Term Investments 980
Long-term Assets Other 9
Long-term Assets  (as reported)174,677
Long-term Assets  (calculated)159,500
+/- 15,177

Liabilities & Shareholders' Equity

Total Current Liabilities39,094
Long-term Liabilities98,706
Total Stockholder Equity368,417
Total Current Liabilities
Short-term Debt 6,176
Accounts payable 4,719
Other Current Liabilities 27,514
Total Current Liabilities  (as reported)39,094
Total Current Liabilities  (calculated)38,409
+/- 685
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt97,360
Long-term Liabilities  (as reported)98,706
Long-term Liabilities  (calculated)97,360
+/- 1,346
Total Stockholder Equity
Common Stock99
Retained Earnings -1,211,732
Accumulated Other Comprehensive Income 15
Other Stockholders Equity 1,580,032
Total Stockholder Equity (as reported)368,417
Total Stockholder Equity (calculated)368,414
+/- 3
Other
Capital Stock102
Cash and Short Term Investments 315,175
Common Stock Shares Outstanding 98,614
Current Deferred Revenue685
Liabilities and Stockholders Equity 506,217
Net Debt 61,666
Net Invested Capital 368,414
Net Working Capital 292,446
Property Plant and Equipment Gross 206,137
Short Long Term Debt Total 103,536



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302011-12-31
> Total Assets 
7,852
0
11,076
0
6,173
23,040
55,583
49,649
43,551
47,010
51,204
44,490
83,483
76,403
67,958
58,705
49,178
49,295
95,048
85,329
73,952
72,675
105,292
93,420
83,155
219,954
213,032
220,865
199,877
340,207
302,274
321,890
653,594
626,443
622,457
1,045,964
1,015,666
984,571
921,455
858,386
807,059
749,349
705,561
630,336
584,757
543,788
506,217
506,217543,788584,757630,336705,561749,349807,059858,386921,455984,5711,015,6661,045,964622,457626,443653,594321,890302,274340,207199,877220,865213,032219,95483,15593,420105,29272,67573,95285,32995,04849,29549,17858,70567,95876,40383,48344,49051,20447,01043,55149,64955,58323,0406,173011,07607,852
   > Total Current Assets 
0
0
9,793
0
4,084
19,386
54,651
48,263
42,245
45,624
49,872
42,792
81,571
74,185
65,652
56,567
47,092
47,399
93,323
83,437
71,861
70,039
102,596
90,625
80,034
213,929
205,196
186,430
165,178
305,633
227,089
208,249
540,225
496,777
494,323
804,316
713,268
693,713
633,412
599,075
599,157
535,329
502,074
437,888
392,182
364,174
331,540
331,540364,174392,182437,888502,074535,329599,157599,075633,412693,713713,268804,316494,323496,777540,225208,249227,089305,633165,178186,430205,196213,92980,03490,625102,59670,03971,86183,43793,32347,39947,09256,56765,65274,18581,57142,79249,87245,62442,24548,26354,65119,3864,08409,79300
       Cash And Cash Equivalents 
6,387
0
9,087
0
3,399
19,082
54,036
47,881
42,012
45,530
49,101
42,349
81,176
72,857
64,809
39,487
35,870
37,099
88,609
40,608
31,063
43,231
88,952
32,912
36,162
183,247
190,514
183,033
71,435
249,588
99,814
83,366
433,074
349,130
167,347
106,413
76,654
129,180
133,583
64,741
55,275
82,093
61,333
42,020
46,802
33,334
41,870
41,87033,33446,80242,02061,33382,09355,27564,741133,583129,18076,654106,413167,347349,130433,07483,36699,814249,58871,435183,033190,514183,24736,16232,91288,95243,23131,06340,60888,60937,09935,87039,48764,80972,85781,17642,34949,10145,53042,01247,88154,03619,0823,39909,08706,387
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,125
10,060
9,520
3,503
41,692
39,950
25,983
11,997
55,722
41,857
27,945
10,493
10,493
90,573
53,235
121,613
119,918
100,335
139,675
315,569
683,722
618,942
549,521
482,327
509,031
513,575
423,043
374,894
366,878
331,133
316,400
273,305
273,305316,400331,133366,878374,894423,043513,575509,031482,327549,521618,942683,722315,569139,675100,335119,918121,61353,23590,57310,49310,49327,94541,85755,72211,99725,98339,95041,6923,5039,52010,06016,125000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
846
0
0
0
0
0
0
0
0
0
500
0
500
500
500
1,687
1,525
0
1,170
1,717
3,243
5,515
6,945
10,303
7,311
8,676
13,850
13,126
10,223
38,480
13,500
2,833
1,538
2,726
2,7261,5382,83313,50038,48010,22313,12613,8508,6767,31110,3036,9455,5153,2431,7171,17001,5251,68750050050005000000000008460000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,687
-1,525
0
-1,170
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000-1,1700-1,525-1,6870000000000000000000000000000
   > Long-term Assets 
0
0
1,283
0
2,089
3,654
932
1,386
1,306
1,386
1,332
1,698
1,912
2,218
2,306
2,138
2,086
1,896
1,725
1,892
2,091
2,636
2,696
2,795
3,121
6,025
7,836
34,435
34,699
34,574
75,185
113,641
113,369
129,666
128,134
241,648
302,398
290,858
288,043
259,311
207,902
214,020
203,487
192,448
192,575
179,614
174,677
174,677179,614192,575192,448203,487214,020207,902259,311288,043290,858302,398241,648128,134129,666113,369113,64175,18534,57434,69934,4357,8366,0253,1212,7952,6962,6362,0911,8921,7251,8962,0862,1382,3062,2181,9121,6981,3321,3861,3061,3869323,6542,08901,28300
       Property Plant Equipment 
1,042
0
1,161
0
930
789
810
1,264
1,159
1,240
1,200
1,544
1,766
2,072
2,160
1,992
1,940
1,750
1,579
1,746
1,945
2,490
2,550
2,649
2,894
3,798
5,125
32,357
32,785
32,813
22,752
81,096
84,161
87,840
67,084
115,245
125,397
139,587
70,720
167,332
171,609
176,496
66,069
173,276
170,074
164,428
158,511
158,511164,428170,074173,27666,069176,496171,609167,33270,720139,587125,397115,24567,08487,84084,16181,09622,75232,81332,78532,3575,1253,7982,8942,6492,5502,4901,9451,7461,5791,7501,9401,9922,1602,0721,7661,5441,2001,2401,1591,26481078993001,16101,042
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
39,440
16,139
0
13,233
0
98,284
149,501
124,877
100,664
67,942
11,925
13,939
4,942
3,912
7,291
0
980
98007,2913,9124,94213,93911,92567,942100,664124,877149,50198,284013,233016,13939,440000000000000000000000000000000
       Long-term Assets Other 
0
0
122
0
1,159
2,865
122
122
147
146
132
154
146
146
146
146
146
146
146
146
146
146
146
146
227
2,227
2,711
2,078
1,914
1,761
12,993
16,406
29,208
28,593
61,050
28,119
27,500
26,394
116,659
24,037
24,368
23,585
132,476
15,260
15,210
9
9
9915,21015,260132,47623,58524,36824,037116,65926,39427,50028,11961,05028,59329,20816,40612,9931,7611,9142,0782,7112,2272271461461461461461461461461461461461461541321461471221222,8651,159012200
> Total Liabilities 
8,226
0
63,901
0
6,323
89,442
4,735
4,472
3,913
13,434
22,864
23,239
32,409
31,408
29,920
27,978
26,049
23,922
21,894
21,471
18,739
26,926
28,103
28,425
31,330
46,025
52,563
75,028
72,351
72,165
57,518
102,672
179,483
202,078
238,012
255,869
263,595
254,239
242,617
224,993
226,576
231,346
221,622
152,864
147,002
141,011
137,800
137,800141,011147,002152,864221,622231,346226,576224,993242,617254,239263,595255,869238,012202,078179,483102,67257,51872,16572,35175,02852,56346,02531,33028,42528,10326,92618,73921,47121,89423,92226,04927,97829,92031,40832,40923,23922,86413,4343,9134,4724,73589,4426,323063,90108,226
   > Total Current Liabilities 
3,675
0
4,850
0
5,427
9,491
4,600
4,354
3,812
3,912
4,581
6,413
11,315
12,596
13,441
13,886
14,327
14,678
15,187
16,897
8,052
9,716
11,049
12,588
16,273
22,672
27,263
29,140
29,418
40,595
27,806
24,924
45,322
54,195
85,564
94,577
105,600
91,884
81,284
77,911
91,518
103,938
114,051
48,651
44,690
41,333
39,094
39,09441,33344,69048,651114,051103,93891,51877,91181,28491,884105,60094,57785,56454,19545,32224,92427,80640,59529,41829,14027,26322,67216,27312,58811,0499,7168,05216,89715,18714,67814,32713,88613,44112,59611,3156,4134,5813,9123,8124,3544,6009,4915,42704,85003,675
       Short-term Debt 
0
0
1,941
0
1,962
5,452
1,732
1,240
746
611
1,546
3,256
5,156
6,494
7,550
7,705
7,864
8,025
8,187
7,620
6,676
14,789
7,254
758
2,011
3,264
2,438
5,141
7,019
15,564
1,692
1,898
2,355
2,330
3,355
4,412
5,068
4,697
5,577
5,582
5,717
5,755
5,628
5,545
5,786
5,977
6,176
6,1765,9775,7865,5455,6285,7555,7175,5825,5774,6975,0684,4123,3552,3302,3551,8981,69215,5647,0195,1412,4383,2642,0117587,25414,7896,6767,6208,1878,0257,8647,7057,5506,4945,1563,2561,5466117461,2401,7325,4521,96201,94100
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
1,535
0
0
0
7,550
7,705
7,864
8,025
8,187
7,620
6,676
14,789
14,808
758
2,011
3,264
2,438
3,941
5,447
13,932
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000013,9325,4473,9412,4383,2642,01175814,80814,7896,6767,6208,1878,0257,8647,7057,5500001,5350000000000
       Accounts payable 
1,863
0
2,519
0
3,326
3,725
682
1,330
980
1,157
645
1,271
1,507
1,280
996
1,975
1,998
1,200
934
2,470
1,177
2,198
1,678
2,160
3,510
5,236
4,205
5,367
5,410
5,715
5,822
5,173
13,563
3,717
6,283
8,998
5,771
6,439
8,612
11,444
8,420
9,593
8,265
9,855
7,506
5,706
4,719
4,7195,7067,5069,8558,2659,5938,42011,4448,6126,4395,7718,9986,2833,71713,5635,1735,8225,7155,4105,3674,2055,2363,5102,1601,6782,1981,1772,4709341,2001,9981,9759961,2801,5071,2716451,1579801,3306823,7253,32602,51901,863
       Other Current Liabilities 
564
0
327
0
118
4,039
94
82
69
57
130
33
2,547
2,371
2,494
2,101
2,360
3,348
3,961
4,702
4,770
5,413
12
7,565
8,976
10,922
13,032
12,056
11,940
15,949
17,505
14,930
14,778
31,027
54,782
60,134
71,729
57,203
45,612
38,310
43,724
53,349
57,932
31,513
29,469
28,540
27,514
27,51428,54029,46931,51357,93253,34943,72438,31045,61257,20371,72960,13454,78231,02714,77814,93017,50515,94911,94012,05613,03210,9228,9767,565125,4134,7704,7023,9613,3482,3602,1012,4942,3712,54733130576982944,03911803270564
   > Long-term Liabilities 
0
0
59,051
0
896
79,951
135
118
101
9,522
18,283
16,826
21,094
18,812
16,479
14,092
11,722
9,244
6,707
4,574
10,687
17,210
17,054
15,837
15,057
23,353
25,300
45,888
42,933
31,570
29,712
77,748
134,161
147,883
152,448
161,292
157,995
162,355
161,333
147,082
135,058
127,408
107,571
104,213
102,312
99,678
98,706
98,70699,678102,312104,213107,571127,408135,058147,082161,333162,355157,995161,292152,448147,883134,16177,74829,71231,57042,93345,88825,30023,35315,05715,83717,05417,21010,6874,5746,7079,24411,72214,09216,47918,81221,09416,82618,2839,52210111813579,951896059,05100
       Long term Debt Total 
0
0
0
0
0
20,250
0
0
0
9,389
18,083
16,414
14,539
12,635
10,688
8,700
6,676
4,610
2,501
1,081
6,676
14,789
14,808
14,069
12,835
11,601
12,446
10,958
9,469
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000009,46910,95812,44611,60112,83514,06914,80814,7896,6761,0812,5014,6106,6768,70010,68812,63514,53916,41418,0839,38900020,25000000
       Capital Lease Obligations Min Short Term Debt
0
0
-1,941
0
-1,962
-5,452
-1,732
-1,240
-746
-611
-1,546
-3,256
-5,156
-6,494
-7,550
-7,705
-7,864
-8,025
-8,187
-7,620
-6,676
-14,789
-7,254
-758
-2,011
-3,264
-2,438
22,576
20,651
11,738
25,235
73,834
78,683
83,156
93,943
106,512
105,405
104,360
109,241
107,939
106,587
105,164
103,710
102,070
100,562
98,977
97,360
97,36098,977100,562102,070103,710105,164106,587107,939109,241104,360105,405106,51293,94383,15678,68373,83425,23511,73820,65122,576-2,438-3,264-2,011-758-7,254-14,789-6,676-7,620-8,187-8,025-7,864-7,705-7,550-6,494-5,156-3,256-1,546-611-746-1,240-1,732-5,452-1,9620-1,94100
       Warrants
0
0
0
0
0
56,526
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000056,52600000
       Long-term Liabilities Other 
0
0
0
0
0
137
0
0
0
57
149
312
478
642
799
942
1,068
1,180
1,276
647
1,414
81
175
267
360
455
549
629
718
1,404
702
790
790
790
800
800
800
800
800
800
800
800
0
0
0
0
0
000008008008008008008008008007907907907021,404718629549455360267175811,4146471,2761,1801,0689427996424783121495700013700000
       Deferred Long Term Liability 
0
0
0
0
0
153
135
118
101
76
51
100
6,077
5,535
4,992
4,450
3,978
3,454
2,930
2,846
2,597
2,340
2,071
1,501
1,462
2,441
3,401
1,851
1,687
1,525
1,338
1,170
13,972
13,357
13,506
12,883
12,264
11,158
9,870
8,777
9,108
8,325
7,196
0
0
0
0
00007,1968,3259,1088,7779,87011,15812,26412,88313,50613,35713,9721,1701,3381,5251,6871,8513,4012,4411,4621,5012,0712,3402,5972,8462,9303,4543,9784,4504,9925,5356,077100517610111813515300000
> Total Stockholder Equity
0
0
-52,825
0
-150
-66,402
50,848
45,177
39,638
33,576
28,340
21,251
51,074
44,995
38,038
30,727
23,129
25,373
73,154
63,858
55,213
45,749
77,189
64,995
51,825
173,929
160,469
145,837
127,526
268,042
244,756
219,218
474,111
424,365
384,445
790,095
752,071
730,332
678,838
633,393
580,483
518,003
483,939
477,472
437,755
402,777
368,417
368,417402,777437,755477,472483,939518,003580,483633,393678,838730,332752,071790,095384,445424,365474,111219,218244,756268,042127,526145,837160,469173,92951,82564,99577,18945,74955,21363,85873,15425,37323,12930,72738,03844,99551,07421,25128,34033,57639,63845,17750,848-66,402-1500-52,82500
   Retained Earnings -1,211,732-1,167,610-1,122,440-1,069,685-1,050,804-994,441-910,878-834,773-769,083-700,462-657,154-602,021-556,932-503,821-445,137-417,065-383,545-355,243-328,634-305,156-285,396-269,369-252,587-232,933-218,798-206,301-195,617-185,972-175,846-167,906-159,169-150,761-142,384-134,938-128,052-120,273-112,392-106,159-99,556-93,489-86,509-80,770-74,9670-65,61500
   Accumulated Other Comprehensive Income 
0
0
-1,749
0
-2,051
-163
-2,296
-2,296
0
0
-2,787
-2,787
0
0
-3,472
14
11
3
-1
-34
-39
-13
-3
-13
-15
-14
-2
-6,325
93
51
22
142
623
312
70
-260
-86
-73
-762
-2,850
-3,381
-3,253
-1,854
-646
-587
-499
15
15-499-587-646-1,854-3,253-3,381-2,850-762-73-86-26070312623142225193-6,325-2-14-15-13-3-13-39-34-131114-3,47200-2,787-2,78700-2,296-2,296-163-2,0510-1,74900
   Capital Surplus 
0
0
0
0
0
14,367
137,337
138,646
139,173
139,714
140,711
141,503
179,097
179,904
180,393
181,445
182,258
193,242
248,957
249,820
250,825
252,019
295,934
297,885
304,371
443,244
445,799
450,925
455,999
623,156
628,200
636,062
918,535
927,784
941,216
1,392,279
1,409,214
1,430,769
1,448,584
1,470,916
1,494,642
1,515,597
0
1,547,702
0
0
0
0001,547,70201,515,5971,494,6421,470,9161,448,5841,430,7691,409,2141,392,279941,216927,784918,535636,062628,200623,156455,999450,925445,799443,244304,371297,885295,934252,019250,825249,820248,957193,242182,258181,445180,393179,904179,097141,503140,711139,714139,173138,646137,33714,36700000
   Treasury Stock00000000000000000000000000000000000000000000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue63,533
Cost of Revenue-18,282
Gross Profit45,25145,251
 
Operating Income (+$)
Gross Profit45,251
Operating Expense-222,862
Operating Income-177,611-177,611
 
Operating Expense (+$)
Research Development143,414
Selling General Administrative81,448
Selling And Marketing Expenses-2,000
Operating Expense222,862222,862
 
Net Interest Income (+$)
Interest Income15,652
Interest Expense-0
Other Finance Cost-0
Net Interest Income15,652
 
Pretax Income (+$)
Operating Income-177,611
Net Interest Income15,652
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-160,928-194,294
EBIT - interestExpense = -177,611
-160,928
-160,928
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-177,611-160,928
Earnings Before Interest and Taxes (EBITDA)-159,329
 
After tax Income (+$)
Income Before Tax-160,928
Tax Provision-0
Net Income From Continuing Ops-173,169-160,928
Net Income-160,928
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses241,144
Total Other Income/Expenses Net16,683-15,652
 

Technical Analysis of Fate Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Fate Therapeutics Inc. The general trend of Fate Therapeutics Inc is BULLISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Fate Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (28.6%) Bearish trend (-28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Fate Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 6.54 < 8.63 < 8.83.

The bearish price targets are: 5.292 > 5.08 > 4.13.

Tweet this
Fate Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Fate Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 9/14.
The longshort score for the Moving Averages is 4/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Fate Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Fate Therapeutics Inc. The current macd is -0.27763409.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Fate Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Fate Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Fate Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Fate Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartFate Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Fate Therapeutics Inc. The current adx is 23.34.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Fate Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Fate Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Fate Therapeutics Inc. The current sar is 6.62277897.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Fate Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Fate Therapeutics Inc. The current rsi is 33.08. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Fate Therapeutics Inc Daily Relative Strength Index (RSI) ChartFate Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Fate Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Fate Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Fate Therapeutics Inc Daily Stochastic Oscillator ChartFate Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Fate Therapeutics Inc. The current cci is -210.98908702.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Fate Therapeutics Inc Daily Commodity Channel Index (CCI) ChartFate Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Fate Therapeutics Inc. The current cmo is -52.68858257.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Fate Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartFate Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Fate Therapeutics Inc. The current willr is -88.9380531.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Fate Therapeutics Inc Daily Williams %R ChartFate Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Fate Therapeutics Inc.

Fate Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Fate Therapeutics Inc. The current atr is 0.5294201.

Fate Therapeutics Inc Daily Average True Range (ATR) ChartFate Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Fate Therapeutics Inc. The current obv is -96,019,348.

Fate Therapeutics Inc Daily On-Balance Volume (OBV) ChartFate Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Fate Therapeutics Inc. The current mfi is 44.97.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Fate Therapeutics Inc Daily Money Flow Index (MFI) ChartFate Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Fate Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-13ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Fate Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Fate Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.081
Ma 20Greater thanMa 506.790
Ma 50Greater thanMa 1006.945
Ma 100Greater thanMa 2005.284
OpenGreater thanClose5.800
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Fate Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Fate Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Fate Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Fate Therapeutics Inc

I send you an email if I find something interesting about Fate Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Fate Therapeutics Inc.

Receive notifications about Fate Therapeutics Inc in your mailbox!